Metavia Inc (MTVA)

$1.75 -0.09 (-4.89%)
Market Cap 9.04M
Revenue (ttm) 0.00
Net Income (ttm) -12.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 81,300
Avg Vol 277,324
Day's Range N/A - N/A
Shares Out 5.16M
Stochastic %K 55%
Beta 0.94
Analysts Strong Sell
Price Target $19.33

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 702 9600
Address:
545 Concord Avenue, Suite 210, Cambridge, United States
LivermoresGhost
LivermoresGhost Aug. 22 at 8:47 PM
$NCNA BUYOUT ALERT: Cavitation Technologies CVAT has execute a binding Definitive Agreement for a buyout for this company. It is waiting for to close Alchemy Beverages deal, with EGS, it will close Monday! This will also add another 40c to the buyout price, makes a total buyout price 11.2c for 287% return. EGS has already show Proof of Funds. The tender will be open 45 days to get total share counts, and then another 30 days for investors to see. Buyout sp: 11.2c Current sp: 3.9c 287% Return on Investment. The tender offer for this will begin Monday! I ask all shareholders to watches this. Please share, and also tell your friends! https://x.com/cvatinfo_/status/2089350022311604396 $IREN $MARA $PWCM $MTVA
0 · Reply
Kertzi
Kertzi Aug. 20 at 4:39 AM
$MTVA Shares outstanding: → 6.59M (Aug 2026). Fully diluted (+ 8.96M warrants outstanding) ≈ 15.5M shares Going concern warning still in the 10-Q. @ZacksSCR target price $30 (right...) 🐻
0 · Reply
Joefreeagent
Joefreeagent Aug. 19 at 5:41 PM
$MTVA Still a scam.
0 · Reply
ShangVXO
ShangVXO Aug. 19 at 1:18 PM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $AIRE & $MTVA too underrated
0 · Reply
ZacksSCR
ZacksSCR Aug. 12 at 4:23 PM
$MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 https://buff.ly/mTXpHUA
0 · Reply
gilsoo
gilsoo Aug. 3 at 1:49 PM
$MTVA Early initiative, foresight, and good fortune have worked nicely for Dong-A, elements any organization can benefit from when outsourcing development and manufacturing. And there’s an interesting aside to add here before we end. Ambiopharm recently announced a $121.9 million investment to expand its South Carolina campus “and bring commercial-scale peptide API production to U.S. soil by 2027.” More good fortune for MetaVia? We’ll be following along.
1 · Reply
Merlintrader
Merlintrader Aug. 1 at 8:14 AM
MetaVia Inc. (Nasdaq: $MTVA) Stock Hub: DA-1726 Q4 2026 Obesity Catalyst, Cash Runway, Warrants and Reverse-Split Risk https://www.merlintrader.com/metavia-inc-stock-hub/
0 · Reply
gilsoo
gilsoo Jul. 31 at 12:58 PM
$MTVA Still acting like a broken record, thinking you know it all. So, did that make you rich yet?
0 · Reply
Kertzi
Kertzi Jul. 27 at 9:57 AM
$MTVA ALL TIME HIGH over $600,000 per share!
0 · Reply
Kertzi
Kertzi Jul. 15 at 7:03 PM
$MTVA Novos Oral Wegovy just got approved in the EU (15 July 2026) — 5th market globally after US, UK, UAE.... 2M+ prescriptions in the US alone, 17% weight loss, already profitable. DA-1726 is still Phase 1. Cash gone Q4. No funding for Phase 2. This "obesity play" might never make it to Phase 2, let alone market — a DECADE behind a drug that's already commercial worldwide. 🐻
0 · Reply
Latest News on MTVA
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 6, 2026, 4:05 PM EDT - 4 weeks ago

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Earnings release: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 4 weeks ago

MetaVia Earnings release: Q2 2026

MetaVia Quarterly report: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 4 weeks ago

MetaVia Quarterly report: Q2 2026

MetaVia Slides: Investor presentation

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

MetaVia Slides: Investor presentation

MetaVia announces completion of dose titration in Phase 1 study of DA-1726

2026-07-09T12:40:47.000Z - 2 months ago

MetaVia announces completion of dose titration in Phase 1 study of DA-1726

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Jul 9, 2026, 8:31 AM EDT - 2 months ago

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Transcript: Life Sciences Virtual Investor Forum

Jun 24, 2026, 10:30 AM EDT - 2 months ago

MetaVia Transcript: Life Sciences Virtual Investor Forum

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

Jun 17, 2026, 8:31 AM EDT - 2 months ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia Transcript: Emerging Growth Conference 93

Jun 11, 2026, 3:40 PM EDT - 2 months ago

MetaVia Transcript: Emerging Growth Conference 93

MetaVia Transcript: AGM 2026

Jun 8, 2026, 10:00 AM EDT - 3 months ago

MetaVia Transcript: AGM 2026

MetaVia presents data at ADA supporting DA-1726, vanoglipel

2026-06-08T12:48:08.000Z - 3 months ago

MetaVia presents data at ADA supporting DA-1726, vanoglipel

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

Jun 8, 2026, 8:31 AM EDT - 3 months ago

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Jun 4, 2026, 8:31 AM EDT - 3 months ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations

2026-05-27T13:33:47.000Z - 3 months ago

MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

May 27, 2026, 8:31 AM EDT - 3 months ago

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

3 Penny Stocks to Watch Now, 5/21/26

2026-05-21T19:20:55.000Z - 3 months ago

3 Penny Stocks to Watch Now, 5/21/26

HCWB SLXN

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

May 20, 2026, 8:00 AM EDT - 3 months ago

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

May 18, 2026, 8:31 AM EDT - 3 months ago

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:05 PM EDT - 3 months ago

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

MetaVia Earnings release: Q1 2026

MetaVia Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

MetaVia Quarterly report: Q1 2026

MetaVia Slides: Investor presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

MetaVia Slides: Investor presentation

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

May 11, 2026, 8:31 AM EDT - 4 months ago

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

MetaVia Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

MetaVia Proxy statement: Proxy filing

MetaVia Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

MetaVia Proxy statement: Proxy filing

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

2026-04-10T12:36:24.000Z - 5 months ago

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

Apr 10, 2026, 8:30 AM EDT - 5 months ago

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

MetaVia: Cash position adequate to fund operations into 4Q26

2026-03-26T12:43:01.000Z - 5 months ago

MetaVia: Cash position adequate to fund operations into 4Q26

MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’

2026-03-26T12:41:30.000Z - 5 months ago

MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

Mar 26, 2026, 8:31 AM EDT - 5 months ago

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

MetaVia Annual report: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 5 months ago

MetaVia Annual report: Q4 2025

MetaVia Earnings release: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 5 months ago

MetaVia Earnings release: Q4 2025

MetaVia Slides: Investor presentation

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MetaVia Slides: Investor presentation

MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study

2026-03-18T12:05:12.000Z - 5 months ago

MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

Mar 18, 2026, 8:00 AM EDT - 5 months ago

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

MetaVia Transcript: Life Sciences Virtual Investor Forum

Mar 12, 2026, 10:30 AM EDT - 5 months ago

MetaVia Transcript: Life Sciences Virtual Investor Forum

MetaVia expands global patent protection for vanoglipel into 2035

2026-03-12T13:09:03.000Z - 5 months ago

MetaVia expands global patent protection for vanoglipel into 2035

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

Mar 12, 2026, 9:01 AM EDT - 5 months ago

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

MetaVia Transcript: Emerging Growth Virtual Conference

Feb 25, 2026, 10:15 AM EST - 6 months ago

MetaVia Transcript: Emerging Growth Virtual Conference

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Feb 13, 2026, 8:31 AM EST - 6 months ago

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

Feb 4, 2026, 8:00 AM EST - 7 months ago

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

Jan 16, 2026, 4:01 PM EST - 7 months ago

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Jan 15, 2026, 9:32 AM EST - 7 months ago

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

MetaVia Registration statement: Registration Filing

Jan 12, 2026, 7:00 AM EST - 7 months ago

MetaVia Registration statement: Registration Filing

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Jan 5, 2026, 8:30 AM EST - 8 months ago

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

MetaVia Registration statement: Registration Filing

Jan 5, 2026, 7:00 AM EST - 8 months ago

MetaVia Registration statement: Registration Filing

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Dec 29, 2025, 8:31 AM EST - 8 months ago

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 22, 2025, 8:31 AM EST - 8 months ago

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Dec 2, 2025, 8:45 AM EST - 9 months ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:31 AM EST - 10 months ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:31 AM EST - 10 months ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

MetaVia Quarterly report: Q3 2025

MetaVia Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

MetaVia Earnings release: Q3 2025

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 27, 2025, 8:31 AM EDT - 10 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 20, 2025, 8:31 AM EDT - 10 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Oct 14, 2025, 8:31 AM EDT - 10 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

MetaVia Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 1 year ago

MetaVia Transcript: H.C. Wainwright 27th Annual Global Investment Conference

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 26, 2025, 8:31 AM EDT - 1 year ago

MetaVia to Present at Upcoming Investor and Industry Conferences

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:31 AM EDT - 1 year ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

MetaVia Quarterly report: Q2 2025

MetaVia Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

MetaVia Earnings release: Q2 2025

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 6, 2025, 8:31 AM EDT - 1 year ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Aug 4, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jul 9, 2025, 8:31 AM EDT - 1 year ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

MetaVia Registration statement: Registration Filing

Jul 2, 2025, 8:00 AM EDT - 1 year ago

MetaVia Registration statement: Registration Filing

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 21, 2025, 9:00 AM EDT - 1 year ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

MetaVia Transcript: Life Sciences Investor Forum

Jun 12, 2025, 1:00 PM EDT - 1 year ago

MetaVia Transcript: Life Sciences Investor Forum

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 10, 2025, 8:31 AM EDT - 1 year ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

MetaVia Proxy statement: Proxy Filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

MetaVia Proxy statement: Proxy Filing

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

Jun 4, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

MetaVia Proxy statement: Proxy Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

MetaVia Proxy statement: Proxy Filing

MetaVia Transcript: Emerging Growth Conference 82

May 21, 2025, 4:25 PM EDT - 1 year ago

MetaVia Transcript: Emerging Growth Conference 82

MetaVia Slides: Investor Presentation

May 21, 2025, 7:00 AM EDT - 1 year ago

MetaVia Slides: Investor Presentation

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 1 year ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

MetaVia Quarterly report: Q1 2025

MetaVia Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

MetaVia Earnings release: Q1 2025

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 9, 2025, 8:01 AM EDT - 1 year ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

May 7, 2025, 2:00 AM EDT - 1 year ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 22, 2025, 8:31 AM EDT - 1 year ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Apr 15, 2025, 7:01 AM EDT - 1 year ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Slides: Investor Presentation

Apr 15, 2025, 7:00 AM EDT - 1 year ago

MetaVia Slides: Investor Presentation

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 7:31 AM EDT - 1 year ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

MetaVia Annual report: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

MetaVia Annual report: Q4 2024

MetaVia Earnings release: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

MetaVia Earnings release: Q4 2024

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

MetaVia Slides: Study Result

Jan 9, 2025, 7:00 AM EST - 1 year ago

MetaVia Slides: Study Result

MetaVia Slides: Investor Presentation

Dec 2, 2024, 7:00 AM EST - 1 year ago

MetaVia Slides: Investor Presentation

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

MetaVia Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

MetaVia Quarterly report: Q3 2024

MetaVia Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

MetaVia Earnings release: Q3 2024

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

LivermoresGhost
LivermoresGhost Aug. 22 at 8:47 PM
$NCNA BUYOUT ALERT: Cavitation Technologies CVAT has execute a binding Definitive Agreement for a buyout for this company. It is waiting for to close Alchemy Beverages deal, with EGS, it will close Monday! This will also add another 40c to the buyout price, makes a total buyout price 11.2c for 287% return. EGS has already show Proof of Funds. The tender will be open 45 days to get total share counts, and then another 30 days for investors to see. Buyout sp: 11.2c Current sp: 3.9c 287% Return on Investment. The tender offer for this will begin Monday! I ask all shareholders to watches this. Please share, and also tell your friends! https://x.com/cvatinfo_/status/2089350022311604396 $IREN $MARA $PWCM $MTVA
0 · Reply
Kertzi
Kertzi Aug. 20 at 4:39 AM
$MTVA Shares outstanding: → 6.59M (Aug 2026). Fully diluted (+ 8.96M warrants outstanding) ≈ 15.5M shares Going concern warning still in the 10-Q. @ZacksSCR target price $30 (right...) 🐻
0 · Reply
Joefreeagent
Joefreeagent Aug. 19 at 5:41 PM
$MTVA Still a scam.
0 · Reply
ShangVXO
ShangVXO Aug. 19 at 1:18 PM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $AIRE & $MTVA too underrated
0 · Reply
ZacksSCR
ZacksSCR Aug. 12 at 4:23 PM
$MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 https://buff.ly/mTXpHUA
0 · Reply
gilsoo
gilsoo Aug. 3 at 1:49 PM
$MTVA Early initiative, foresight, and good fortune have worked nicely for Dong-A, elements any organization can benefit from when outsourcing development and manufacturing. And there’s an interesting aside to add here before we end. Ambiopharm recently announced a $121.9 million investment to expand its South Carolina campus “and bring commercial-scale peptide API production to U.S. soil by 2027.” More good fortune for MetaVia? We’ll be following along.
1 · Reply
Merlintrader
Merlintrader Aug. 1 at 8:14 AM
MetaVia Inc. (Nasdaq: $MTVA) Stock Hub: DA-1726 Q4 2026 Obesity Catalyst, Cash Runway, Warrants and Reverse-Split Risk https://www.merlintrader.com/metavia-inc-stock-hub/
0 · Reply
gilsoo
gilsoo Jul. 31 at 12:58 PM
$MTVA Still acting like a broken record, thinking you know it all. So, did that make you rich yet?
0 · Reply
Kertzi
Kertzi Jul. 27 at 9:57 AM
$MTVA ALL TIME HIGH over $600,000 per share!
0 · Reply
Kertzi
Kertzi Jul. 15 at 7:03 PM
$MTVA Novos Oral Wegovy just got approved in the EU (15 July 2026) — 5th market globally after US, UK, UAE.... 2M+ prescriptions in the US alone, 17% weight loss, already profitable. DA-1726 is still Phase 1. Cash gone Q4. No funding for Phase 2. This "obesity play" might never make it to Phase 2, let alone market — a DECADE behind a drug that's already commercial worldwide. 🐻
0 · Reply
stocktraderbegins
stocktraderbegins Jul. 14 at 2:41 PM
$SPY $MTVA great price 🔥🙏💙 Lets ride it up !!!
0 · Reply
Merlintrader
Merlintrader Jul. 14 at 10:46 AM
$MTVA MetaVia Stock Hub - DA-1726 obesity data, the Q4 2026 Phase 1 Part 3 catalyst, the Dong-A ST Korea link, and the dilution equation https://www.merlintrader.com/metavia-inc-stock-hub/
1 · Reply
MACnTEEZ
MACnTEEZ Jul. 13 at 7:51 PM
$MTVA theres an offering filed
2 · Reply
stockWare
stockWare Jul. 13 at 4:47 PM
$MTVA this biotech is working on a GLP-1 analog $LLY $HIMS $NVO
1 · Reply
stockWare
stockWare Jul. 13 at 4:45 PM
$MTVA got a small position, feels like HC Wainwright is going to bring this to the next level soon and we could be back near 52 week highs very soon. $IWM
0 · Reply
Reliantroofing
Reliantroofing Jul. 13 at 4:20 PM
$MTVA that's how Chinese people make the dollars pump and dump always
1 · Reply
Kertzi
Kertzi Jul. 13 at 4:15 PM
$MTVA MASSIVE PUMP & DUMP! It seems that the next offering has been decided, at which point toxic lenders pumped up the stock price to maximize their profits, before the new shares hit the market. The SEC should investigate these cases, but it’s a waste of time—who cares about a fake Korean pharma company with eight employees?
1 · Reply
Kertzi
Kertzi Jul. 13 at 3:22 PM
$MTVA
0 · Reply
stocktraderbegins
stocktraderbegins Jul. 13 at 3:16 PM
$SPY $MTVA is going offf pile in !!!!
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 13 at 3:11 PM
$MTVA $ALP $SOBR $BRAI $QTTB Great Moves too
0 · Reply
FaithFilledTrader
FaithFilledTrader Jul. 13 at 3:05 PM
$MTVA 🤔
0 · Reply